Tonix Pharmaceuticals saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 88 to 92.
Here Are 3 Keys For Successful Stock Investing
This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matches up against other publicly traded companies.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an RS Rating north of 80 at the beginning of a new run.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock goes on to offer and clear an appropriate buy point.
Tonix Pharmaceuticals reported 0% earnings growth in its most recent report. Sales rose -2%.
Tonix Pharmaceuticals earns the No. 102 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
